[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneurysm-cerebral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneurysm-cerebral":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,77,103,130,157,188,215,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100471498","interest-of-a-simulated-procedure-performed-on-a-printed-model-in-the-endovascular-treatment-of-carotid-sylvian-aneurysms-100471498",false,"NCT05419661","Interest of a Simulated Procedure Performed on a Printed Model in the Endovascular Treatment of Carotid-sylvian Aneurysms","Evaluation of the Interest of a Simulated Procedure Performed on a Printed Model in the Endovascular Treatment of Carotid-sylvian Aneurysms","Anev3D","Inclusion Criteria:\n\n* Patient over 18 years old\n* Social security affiliation\n* Patient who signed inform consent form\n* Patient with an unruptured saccular carotid-sylvian aneurysm of more than 4 mm in long axis and less than 20 mm\n* Primary preventive treatment decision validated in CPR\n* Patient having benefited from a 3DRA during a previous arteriography dating from less than 6 months, or whose cerebral arteriography is planned less than 2 weeks before the intervention\n\nExclusion Criteria:\n\n* Unable or unwilling to come for follow-up appointments\n* Weight \\> 250kg due to weight limits on the angiographic table\n* Allergy to iodinated contrast agents\n* Patient with a contraindication to MRI\n* Pregnancy, breastfeeding or planning to become pregnant in the following year\n* Limited life expectancy \\\u003C 1 year\n* Patient participating in another clinical study or having completed their participation less than 30 days ago\n* Patient under legal protection, Patient under guardianship or curatorship\n* Kidney failure, GFR \\\u003C 60ml\u002Fmin\u002F1.73 m2\n* Platelets \\\u003C 50 x 10 \\^ 9\u002FL\n* Partially thrombosed aneurysm\n* Partially calcified aneurysm\n* Recanalized or previously treated aneurysm (coils, stent, clip, flow disrupter)\n* Another aneurysm on the same carrier artery already treated (coils, stent, clip, flow disrupter)\n* Ruptured aneurysm","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","It is now considered that 1% to 2% of the French population has an intracranial aneurysm. The major risk of this malformation is essentially the rupture which will lead in 10% of cases to death immediately, in 30% to 50% death within three weeks and in 30% of cases the patients will present a permanent disability. The management of this pathology represents today a major health challenge. Historically, neurosurgery was the discipline of first choice for the treatment of this pathology. This consists of clipping the aneurysm by a surgical approach to exclude it from the blood circulation and thus avoid its rupture. For many years now, interventional neuroradiology has established itself, through its \"minimally invasive\" and endovascular approach, as the reference treatment for ruptured and non-ruptured intracranial aneurysms: this is embolization. This so-called minimally invasive technique consists of placing directly into the aneurysm, using micro-catheters that are navigated under radiological control from the femoral artery, turns of plates called \"coils\" or prostheses called \" stent\" or \"flow-diverter\". This technique makes it possible to secure the aneurysm from the inside and thus reduce the risk of rupture. Today, 95% of patients are treated using this innovative technique and limited intraoperative risks. Interventional neuroradiology has constantly known in recent years a set of revolutions and innovations in terms of implantable medical devices (IMD) allowing to treat more and more patients with excellent clinical results. Today, the interventional neuroradiologist, assisted by the radiographer, has a very wide range of IMDs that he can combine with each other depending on the type, location, size and shape of the aneurysm. The role of the manipulator, here, is to work closely with the neuroradiologist so that he has, on the one hand, quality images and on the other hand, that he can count on a precious ally, an expert in IMDs, during embolization procedures. However, the wide choice of medical devices and the complexity of the aneurysms to be treated sometimes make treatment complicated. On the day of the \"cold\" treatment of the aneurysm (i.e. non-ruptured), the technicality of the catheterization and aneurysm's spatial conformation complicates the deployment of embolization equipment. This then sometimes leads to undesirable events such as intraoperative rupture. The very purpose of this study is to be able, by means of a 3D printer, to print the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus proceed to a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.",[27],"Aneurysm Cerebral",[29,30,31,32],"Operational Pre-Planning","embolization","3D printer","carotid-sylvian aneurysm","NOT_YET_RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-09","ACTUAL",{"date":39,"type":21},"2026-12-01",{"date":41,"type":21},"2029-06-01",{"name":43,"class":44},"University Hospital, Brest","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100578009","this-three-year-observational-study-involves-patients-of-all-ages-undergoing-endovascular-treatment-for-various-cerebral-or-spinal-vascular-conditions-it-aims-to-assess-pre--and-post-operative-clinical-conditions-report-complications-and-identify-preoperative-indicators-of-treatment-outcomes-pat-100578009","NCT06805721","This Three-year Observational Study Involves Patients of All Ages Undergoing Endovascular Treatment for Various Cerebral or Spinal Vascular Conditions. It Aims to Assess Pre- and Post-operative Clinical Conditions, Report Complications, and Identify Preoperative Indicators of Treatment Outcomes. Pat","OUTCOME IN NEURORADIOLOGIA INTERVENTISTICA INDICAZIONI COMPLICANZE (ONIRIC)","ONIRIC","Inclusion Criteria:\n\n* Patients of both sexes and any age, who are referred to the Department of Neurosurgery and Clinical Neurosciences and are candidates for interventional endovascular procedures for any cerebral or spinal pathology, will be included in the study.\n\nExclusion Criteria:\n\n* \u002F",{"count":55,"type":21},1000,"OBSERVATIONAL","This three-year observational study involves patients of all ages undergoing endovascular treatment for various cerebral or spinal vascular conditions. It aims to assess pre- and post-operative clinical conditions, report complications, and identify preoperative indicators of treatment outcomes. Patients will also receive psychological support and Neuropsychological assessment. Clinical, medical, and demographic data will be recorded in a database during hospitalization and follow-up visits.",[27,59,60,61],"AVM","DAFV","ESDC",[63,64,65,59,66],"Endovascular treatment","Neurospychological assessment","Aneurysm","Psychological Outcome","RECRUITING","2026-03-25",{"date":70,"type":37},"2026-03-27",{"date":72,"type":37},"2023-02-06",{"date":74,"type":21},"2029-01",{"name":76,"class":44},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100599568","perioperative-risk-in-patients-on-chronic-aspirin-undergoing-craniotomy-100599568","NCT07086183","Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy","Assessing Surgical Perioperative rIsk in Patients on chRonic aspIrN Therapy Undergoing Elective Craniotomy for Aneurysm Clipping: a Prospective Multi-center Observational Study (ASPIRIN)","ASPRIN","Inclusion Criteria:\n\n* Age \\> or = 18 years old\n* Patients willing to participate and provide an informed consent\n* Patients undergoing elective craniotomy for cerebral aneurysm clipping\n* Patients on chronic low-dose (75-100 mg) aspirin daily (aspirin group) or not on aspirin therapy for at least 7 days (control group) preoperatively.\n\nExclusion Criteria:\n\n* Emergency craniotomy\n* Use of other antiplatelet or anticoagulant medications within 7 days prior to surgery\n* Known bleeding disorders (e.g. hemophilia, thrombocytopenia)\n* History of intracranial hemorrhage unrelated to aneurysm\n* Inability to provide informed consent",{"count":86,"type":21},100,"This study is looking at how taking aspirin regularly affects bleeding during and after brain surgery. Specifically, it focuses on patients who are having elective surgery to clip a brain aneurysm.\n\nAspirin is commonly used to prevent heart attacks and strokes, but it can also increase the risk of bleeding. Doctors often face a tough decision: should patients stop taking aspirin before surgery to reduce bleeding risk, or continue it to prevent blood clots?\n\nTo help answer this question, researchers will observe 100 patients, some who take aspirin regularly and some who don't, at hospitals in the U.S., Russia, and Italy. They will not change any treatments but will collect information about bleeding during surgery, blood test results, and CT scans after surgery.\n\nThe goal is to better understand the risks of continuing aspirin and to help doctors make safer decisions for future patients.",[27],[90,91,92,93],"craniotomy","aneurysm clipping","aspirin","postoperative bleeding","2026-01-05",{"date":96,"type":37},"2026-01-07",{"date":39,"type":21},{"date":99,"type":21},"2027-12-01",{"name":101,"class":44},"Mayo Clinic",3,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100612856","lumens-1-canada-early-feasibility-study-clinical-investigation-plan-100612856","NCT07259018","LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan","A Single-arm, Open Label, Single-center Early Feasibility Study of the LuSeed Aneurysm Embolization System in Individuals With Unruptured Intracranial Aneurysms.","Inclusion Criteria:\n\n1. Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA \u002F ASA Guidelines.\n2. Age 18-80 years at screening\n3. Patients who are suitable for non-emergency endovascular embolization of saccular IAs\n4. The IA must have had the following characteristics:\n\n   * IA located in bifurcation in the anterior or posterior circulation\n   * IA dimensions appropriate for treatment with LuSeed- Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for\n\n   Use (IFU) and as follows:\n   * IA Width: 2.5-5.5\\[mm\\]\n   * IA Neck: 2.0-5.0\\[mm\\]\n   * IA Height: min 4.0 \\[mm\\]- device short configuration, min 5.0 \\[mm\\]-device long configuration • The AI must meet the definition of a \"wide-neck\" aneurysm.\n5. Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements\n6. Patient able to give their informed consent can be included in this study.\n\nExclusion Criteria:\n\n1. Ruptured intracranial aneurysm\n2. Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab\n3. Contraindication for arterial access\n4. Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm\n5. Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm\n6. Intracranial aneurysm minimum height less than 4.0 mm\n7. Target Intracranial aneurysm contains other devices\u002Fimplants (e.g., coils)\n8. Stenosis of the target IA's parent vessel \\>50%\n9. Known allergy to platinum, nickel, or titanium\n10. Known allergy to contrast agents\n11. Absolute contraindication to anticoagulation or antiplatelet therapy\n12. Anticoagulation medications such as warfarin that cannot be discontinued\n13. Pregnant, breastfeeding or planning pregnancy within next 12 months\n14. Acute or chronic renal failure (stage III or IV by VARC-3 criteria)\n15. Cerebral embolism, stroke, or TIA in past 6 months\n16. Myocardial infarction in the past 6 months\n17. Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)\n18. Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.\n19. Patient had physical, neurologic or psychiatric conditions which precluded his\u002Fher ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.\n20. Other medical conditions that cause an inability to comply with study requirements and\u002For that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)\n21. Patient had a life expectancy of less than 12 months.\n22. Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.","80 Years",{"count":112,"type":21},10,[24],"The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a single-arm, open-label, single-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 10 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled in a Canadian site.",[27,116,117,118,119],"Bifurcation","Unruptured Intracranial Aneurysm","Saccular Aneurysm","Brain Aneurysm","2025-12-02",{"date":122,"type":37},"2025-12-09",{"date":124,"type":21},"2025-12",{"date":126,"type":21},"2028-05",{"name":128,"class":129},"LuSeed Vascular LTD.","INDUSTRY",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100574598","lumens-1-eu-efs-cip-100574598","NCT06761365","LUMENS-1 EU EFS CIP","A SINGLE-ARM, OPEN LABEL, MULTI-CENTER EARLY FEASIBILITY STUDY OF THE LUSEED ANEURYSM EMBOLIZATION SYSTEM IN INDIVIDUALS WITH UPRUPTURED INTRACRANIAL ANEURYSMS","Inclusion Criteria:\n\n* Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA \u002F ASA Guidelines.\n\n  1. Age 18-80 years at screening\n  2. Patients who are suitable for non-emergency endovascular embolization of saccular IAs\n  3. The IA must have had the following characteristics:\n* IA located in the anterior or posterior circulation\n* IA dimensions appropriate for treatment with\n\nLuSeed-Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for Use (IFU) and as follows:\n\n* IA Width: 2.5-5.5\\[mm\\]\n* IA Neck: 2.0-5.0\\[mm\\]\n* IA Height: min 4.0 \\[mm\\]- device short configuration, min 5.0 \\[mm\\]-device long configuration 4. Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements Exclusion Criteria: 5. Patient able to give their informed consent can be included in this study. Exclusion Criteria\n\n  1. Ruptured intracranial aneurysm\n  2. Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab\n  3. Contraindication for arterial access\n  4. Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm\n  5. Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm\n  6. Intracarnial aneurysm minimum hight less than 4.0 mm\n  7. Target Intracranial aneurysm contains other devices\u002Fimplants (e.g., coils)\n  8. Stenosis of the target IA's parent vessel \\>50%\n  9. Known allergy to platinum, nickel, or titanium\n  10. Known allergy to contrast agents\n  11. Absolute contraindication to anticoagulation or antiplatelet therapy\n  12. Anticoagulation medications such as warfarin that cannot be discontinued\n  13. Pregnant, breastfeeding or planning pregnancy within next 12 months\n  14. Acute or chronic renal failure (stage III or IV by VARC-3 criteria)\n  15. Cerebral embolism, stroke, or TIA in past 6 months\n  16. Myocardial infarction in the past 6 months\n  17. Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)\n  18. Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.\n  19. Patient had physical, neurologic or psychiatric conditions which precluded his\u002Fher ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.\n  20. Other medical conditions that cause an inability to comply with study requirements and\u002For that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)\n  21. Patient had a life expectancy of less than 12 months .\n  22. Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.",{"count":138,"type":21},30,[24],"The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a prospective, single-arm, open-label, multi-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 30 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled across a maximum of 10 medical centers in the EU.",[27,116,117,118,119],[116,143,144,145,146,147],"Embolization","Flow Diverter","Intrasaccular Device","Cerebral Aneurysm","Unruptured","2025-11-21",{"date":150,"type":37},"2025-11-26",{"date":152,"type":37},"2024-10-07",{"date":154,"type":21},"2027-06",{"name":128,"class":129},6,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100525560","psychiatric-outcomes-of-unruptured-intracranial-aneurysms-pouia-100525560","NCT06123325","Psychiatric Outcomes of Unruptured Intracranial Aneurysms (POUIA)","Impact of Observation Versus Treatment on The Psychiatric and Mental Outcomes of Patients With Unruptured Intracranial Aneurysms","POUIA","Inclusion Criteria:\n\n* Unruptured intracranial aneurysms (UIA)\n* mRS scores between 0-1\n* Observation Group: All patients with UIAs that are eligible for conservative management\n\n  1. Specific locations that are not good candidates for interventional treatment, such as cavernous internal carotid artery and very distally located aneurysms\n  2. Aneurysm size (largest dimension) is less than 4 mm\n* Treatment Group: All patients with UIAs that are decided to be treated either with endovascular or microsurgical treatments due to several reasons, such as aneurysm size above 4 mm, patient's decision\n\nExclusion Criteria:\n\n* Prior history of Subarachnoid Hemorrhage (SAH)\n* Prior history of intracranial aneurysm\n* Severe comorbidities that impact the mental health of the patients, such severe psychiatric disease, and chronic end stage diseases\n* Traumatic, mycotic, dissecting, or fusiform aneurysms\n* Patients with communication barriers (does not include foreign language), developmental disability, or psychiatric illness that prevent understanding of the questions required to complete assessments\n* Patients with any physical disabilities or handicaps","75 Years",{"count":167,"type":21},120,[24],"The impact of cerebrovascular procedures on patients experiencing anxiety and depression is not well studied despite the high prevalence of these mental health disorders. Unruptured Intracranial aneurysms (UIAs) have a prevalence of approximately 3% and an annual risk of 1-2% in the general population. Despite the high risk of fatality following aneurysm rupture with a rate of 40-50%, the overall aneurysm growth and rupture risks are rare (less than 3% per aneurysm per year) and many patients can be observed with serial follow-up imaging over years. Nevertheless, due to the gravity of the bad consequences of aneurysm rupture, simply informing many patients of UIA diagnosis has been found to result in worse outcomes of health-related quality of life. This study aims to investigate the impact of awareness of untreated UIA on the patients' mental health utilizing the Hospital Anxiety and Depression Scale (HADS) tool.",[171,27,172],"Anxiety Depression","Mental Health Wellness 1",[174,175,176,177,178],"Cerebral aneurysm","Anxiety","Depression","Endovascular","Clipping","2025-11-16",{"date":181,"type":37},"2025-11-19",{"date":183,"type":37},"2023-12-01",{"date":185,"type":21},"2027-09",{"name":187,"class":44},"Montefiore Medical Center",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":196,"maxAge":110,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":102},"100599089","phase-1-study-to-evaluate-the-tube-device-ability-to-treat-unruptured-wide-neck-or-fusiform-aneurysms-100599089","NCT07079956","Study to Evaluate the TUBE Device Ability to Treat Unruptured, Wide-neck or Fusiform Aneurysms","A Prospective, Single-Arm, Multicenter, Feasibility Trial to Evaluate the Safety and Performance of the TUBE Device in the Endovascular Treatment of Unruptured, Wide-Neck or Fusiform Intracranial Aneurysms","NV01","Inclusion Criteria:\n\n1. Has a single unruptured target intracranial aneurysm (IA) with the following characteristics:\n\n   1. Is located on the internal carotid artery or its branch-es.\n   2. Has a neck ≥ 4 mm, dome to neck ratio \\\u003C 2.0, or no discernible neck\n   3. Aneurysm diameter ≤ 35 mm (saccular or fusiform configuration)\n2. Has a parent vessel diameter ≥ 2.0 mm and ≤ 5.0 mm at both the proximal and distal segments where the implant will be placed.\n3. Has multiple increased risk factors for intracranial aneurysm rupture, including but not limited to, aneurysm morphology, smoking, hypertension, diabetes, age, prior and\u002For family history of aneurysm rupture, and\u002For history of subarachnoid hemorrhage that may result in a benefit risk profile of endovascular treatment that outweighs the risks of intracranial aneurysm rupture during the patient's expected lifetime if left untreated.\n4. The patient is able and willing to provide written in-formed consent.\n\nExclusion Criteria:\n\nParticipants are not eligible for the study if ANY of the following criteria are present:\n\n1. Has an extradural aneurysm\n2. Has a target aneurysm in the posterior circulation\n3. Perforator or branch vessel, inclusive of the posterior communicating artery, arises from the target aneurysm body or neck (branches or arteries must arise or connect from the parent vessel separate from the aneurysm or neck to not be excluded from study)\n4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at a point of vessel bifurcation\n5. Target aneurysm is unsuitable for flow diverter treatment\n6. Has vessel characteristics, such as severe tortuosity (cICA Type IV), stenosis (\\>70%), or morphology that would preclude safe endovascular access to the target aneurysm necessary for treatment with the study device\n7. Received previous treatment of the target aneurysm or parent artery where it would interfere with the placement or proper apposition of the device\n8. Has a medical contraindication to study or procedure related antiplatelet medications (aspirin, clopidogrel\u002F Plavix, prasugrel, ticagrelor, and heparin), local or general anesthesia, or life-threatening allergy to contrast dye\n9. Non-responders to prasugrel as determined by the P2Y12 assay (\"VerifyNow\" system)\n10. Has a known severe allergy to nickel titanium, stainless steel (304SS) tantalum, or platinum.\n11. Modified Rankin Score assessment is ≥ 3 at pre-procedure exam\n12. Presence of unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days)\n13. Subarachnoid hemorrhage occurred within 30 days prior to enrollment\n14. Major surgery (including previous intracranial implant) occurred within previous 30 days or is planned in the next 120 days after enrollment date\n15. Has more than one intracranial aneurysm that requires treatment within 12 months\n16. Received previous intracranial implant associated with the symptomatic or vascular distribution within the past 12 weeks prior to treatment date\n17. Chronic anticoagulation therapy is ongoing or known coagulopathy exists\n18. Has other known serious concurrent medical conditions such as heart disease (e.g., atrial fibrillation \\[with or without pacemaker\\], recent myocardial infarction \\[\\\u003C 12 weeks ago\\], symptomatic congestive heart failure, or carotid stenosis), kidney failure \\[\\>2.0mg\u002Fdl serum creatinine\\], pulmonary disease, uncontrolled diabetes, progressive neurologic disorders, terminal cancer, vasculitis, high risk of ischemic stroke or recent stroke\n19. Has acute life-threatening illness other than the neurological disease (e.g., acute kidney or heart failure) to be treated in this trial\n20. Life expectancy is less than 5 years due to other illness or condition (in addition to an intracranial aneurysm)\n21. Unable to complete study follow up due to dementia or psychiatric problem, substance abuse, or history of noncompliance with medical advice\n22. Pregnancy at time of enrollment\n23. Presence of intracranial mass (tumor, except meningioma, abscess, or other infection), non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm\n24. Evidence of active infection at the time of treatment\n25. Enrollment in another trial involving an investigational product that could confound the outcomes of this trial.","22 Years",{"count":198,"type":21},20,[200],"PHASE1","To assess the safety and performance of the TUBE device in the endovascular treatment of unruptured, wide-neck or fusiform intracranial aneurysms located on the internal carotid artery (ICA) or its branches",[27],[65,204,205,144],"Wide-neck","Fusiform","2025-07-14",{"date":208,"type":37},"2025-07-23",{"date":210,"type":21},"2025-10",{"date":212,"type":21},"2026-10",{"name":214,"class":129},"NVMedTech",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":225,"conditions":226,"keywords":230,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100596815","the-risk-factors-related-to-rupture-flow-related-aneurysms-in-posterior-avm-100596815","NCT07050381","The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM","Risk Factors Related to Rupture Flow-related Aneurysms in Posterior Arteriovenious Malformation: A Muti-center Observentional Research.","pAVM-rFA","Inclusion Criteria:\n\n1. pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT\n2. No history of stroke, Marfan syndrome, polycystic kidney disease\n\nExclusion Criteria:\n\n1. pAVM without flow-related aneurysms\n2. Absence of clinical data",{"count":224,"type":21},200,"AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.",[227,228,229,27],"Arteriovenous Malformation of Central Nervous System","Aneurysm, Ruptured","Aneurysmatic Subarachnoid Haemorrhage",[231,232,233,234],"arteriovenous malformation","flow-related aneurysm","ruptured aneurysm","subarachnoid hemorrhage","2025-06-25",{"date":237,"type":37},"2025-07-03",{"date":239,"type":37},"2025-06-13",{"date":241,"type":21},"2026-12-31",{"name":243,"class":44},"The First Affiliated Hospital with Nanjing Medical University",2,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":45},"100518656","blood-pressure-treatment-in-icu-patients-with-subarachniodal-haemorrhage-100518656","NCT06033378","Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage.","Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage. -Can Blood Pressure Be Used As a Surrogate Marker for Blood Flow","BFBP","Inclusion Criteria:\n\n* Coiled or clipped aneurysm\n* Suspected or confirmed vasospasm\n\nExclusion Criteria:\n\n* BMI \\>30\n* Pregnancy\n* Pacemaker or other MRI contraindications\n* Severe congestive heart failure (NYHA III-IV) or cardiac arrhythmia.\n* Severe respiratory failure or FiO2 \\>0.6\n* Severe kidney failure",{"count":138,"type":21},[24],"An MRI study to examine the relationship between blood pressure and cerebral blood flow in patients with subarachnoidal hemorrhage and suspect or verified vasospasm.",[257,258,27],"Blood Pressure","Subarachnoid Hemorrhage",[260,261,262],"magnetic resonance imaging","norepinephrine","blood flow","2025-03-10",{"date":265,"type":37},"2025-03-13",{"date":267,"type":37},"2023-09-01",{"date":269,"type":21},"2028-09-01",{"name":271,"class":44},"Umeå University"]